Online citations, reference lists, and bibliographies.
← Back to Search

Breast Cancer Subtypes And The Risk Of Local And Regional Relapse.

K. D. Voduc, M. Cheang, S. Tyldesley, K. Gelmon, T. Nielsen, H. Kennecke
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays. PATIENTS AND METHODS Semiquantitative analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 was performed on tissue microarrays constructed from 2,985 patients with early invasive breast cancer. Patients were classified into the following categories: luminal A, luminal B, luminal-HER2, HER2 enriched, basal-like, or triple-negative phenotype-nonbasal. Multivariable Cox analysis was used to determine the risk of local or regional relapse associated the intrinsic subtypes, adjusting for standard clinicopathologic factors. RESULTS The intrinsic molecular subtype was successfully determined in 2,985 tumors. The median follow-up time was 12 years, and there have been a total of 325 local recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR positive, HER2 negative, Ki-67 < 1%) had the best prognosis and the lowest rate of local or regional relapse. For patients undergoing breast conservation, HER2-enriched and basal subtypes demonstrated an increased risk of regional recurrence, and this was statistically significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-enriched, and basal subtypes were all associated with an increased risk of local and regional relapse on multivariable analysis. CONCLUSION Luminal A tumors are associated with a low risk of local or regional recurrence. Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.
This paper references
10.1016/S0360-3016(02)02973-5
Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer.
P. Truong (2002)
Elderly breast
G Martelli
10.3816/CBC.2008.n.028
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
S. Crabb (2008)
10.1002/cncr.23213
Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen
G. Martelli (2008)
10.1016/S0360-3016(99)00158-3
Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression.
P. H. M. Elkhuizen (1999)
10.1016/S0140-6736(05)67887-7
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
M. Clarke (2005)
Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20
E Mamounas (2005)
10.1002/cncr.11915
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence
Bruce G. Haffty (2004)
10.1093/ANNONC/MDH434
Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies.
M. Colleoni (2004)
10.1186/bcr1636
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival
L. Fulford (2006)
10.1016/J.IJROBP.2004.09.013
Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy.
P. Truong (2005)
10.1056/NEJM199710023371402
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
J. Ragaz (1997)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
J. (2002)
patients treated by conservative surgery alone plus adjuvant tamoxifen : Fifteen - year results of a prospective study
SJ Crabb (2008)
10.1016/J.IJROBP.2006.07.027
Predicting the risk of local recurrence in patients with breast cancer: an approach to a new computer-based predictive tool.
M. Sanghani (2007)
10.1200/JCO.2000.18.9.1906
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.
R. Zellars (2000)
10.1056/NEJM199710023371401
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
M. Overgaard (1997)
10.1038/415530a
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)
10.1158/1078-0432.CCR-04-0220
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
10.1016/S0959-8049(01)00165-4
Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.
A. Ringberg (2001)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1158/1078-0432.CCR-06-3045
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
10.1016/J.JSS.2006.10.045
p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
M. D. de Roos (2007)
10.1200/JCO.2007.14.5565
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
M. Kyndi (2008)
10.1016/S0959-8049(98)80408-5
Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer.
J. Jager (2000)
10.1200/JCO.2005.05.4155
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
M. Cheang (2006)
10.1200/JCO.2007.14.4287
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
P. Nguyen (2008)
10.1067/MSY.2001.116921
Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers.
T. Hieken (2001)
10.1200/JCO.1997.15.1.216
Compliance with practice guidelines for node-negative breast cancer.
A. Olivotto (1997)
10.1016/S0140-6736(98)09201-0
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
M. Overgaard (1999)
10.1016/S0248-8663(97)83705-8
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
C. Louvet (1998)
10.1038/sj.bjc.6600755
Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?
M. Koukourakis (2003)
10.1200/JCO.2006.06.5664
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
B. Haffty (2006)
10.1073/pnas.0932692100
Repeated observation of breast tumor subtypes in independent gene expression data sets
T. Sørlie (2003)
10.1158/1078-0432.CCR-07-1658
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
M. Cheang (2008)
10.1200/JCO.2008.21.7075
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
E. Millar (2009)
10.1186/bcr1614
Predicting a local recurrence after breast-conserving therapy by gene expression profiling
D. Nuyten (2006)
10.1186/bcr1531
Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study
Michelle K Nottage (2006)
10.1056/NEJMC076272
Local therapy and survival in breast cancer.
B. Fisher (2007)
10.1056/NEJMOA041588
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
S. Paik (2004)
10.1093/jnci/djp082
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
M. Cheang (2009)
10.1158/1078-0432.CCR-07-0450
Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact
P. Casalini (2008)
10.1002/SIM.4780131603
Statistical analysis of proliferative index data in clinical trials.
P. Grambsch (1994)



This paper is referenced by
10.1371/journal.pone.0086676
Preoperative Measurement of Breast Cancer Overestimates Tumor Size Compared to Pathological Measurement
Y. Jiang (2014)
10.1371/journal.pone.0158461
Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
E. Y. Chae (2016)
10.1371/journal.pone.0076379
Tumor Secretion of CCL22 Activates Intratumoral Treg Infiltration and Is Independent Prognostic Predictor of Breast Cancer
Y. Li (2013)
10.1016/j.diii.2013.06.011
Perfusion studies in senology.
C. de Bazelaire (2013)
10.1016/j.ejso.2013.05.004
Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer.
M. V. D. van der Sangen (2013)
10.1016/j.jogoh.2018.10.014
Survival impact of primary site surgery on metastatic breast cancer patients at diagnosis.
H. Desille-Gbaguidi (2019)
10.1093/bib/bby115
Multilevel heterogeneous omics data integration with kernel fusion
H. Yang (2020)
10.1007/s10549-017-4583-z
Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up
Karama Asleh (2017)
10.1186/s12885-016-2766-3
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
A. Hennigs (2016)
10.7314/APJCP.2016.17.3.1261
Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.
M. Payandeh (2016)
Polimorfismo genético do fator de transcrição FOXP3 em pacientes com câncer de mama
Caroline Yukari Motoori-Fernandes (2019)
10.1016/J.JONS.2017.11.004
Serum endocan level and its prognostic significance in breast cancer patients
O. Ates (2018)
10.1002/JRS.5201
Discrimination of tumor from normal tissues in a mouse model of breast cancer using CARS spectroscopy combined with PC‐DFA methodology
Xi S. Huang (2017)
10.1007/978-3-319-26012-9_11
Adjuvant Radiation Therapy After Preoperative Chemotherapy
M. Fayda (2016)
10.2147/BCTT.S111098
Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
Roberta Piva (2017)
10.3109/9781841848129-7
Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer
Sarah M. Barton (2011)
10.1016/j.critrevonc.2016.12.006
How could breast cancer molecular features contribute to locoregional treatment decision making?
P. G. Tsoutsou (2017)
Tumor-associated macrophages and microglia : double-edged sword in tumor evolvement and invasion
Tatjana Wallmann (2018)
10.14288/1.0072704
Algorithms and applications of next-generation DNA sequencing : ChIP-Seq, database of human variations, and analysis of mammary ductal carcinomas
Anthony P. Fejes (2012)
Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015 he ACOSOG-Z 0011 and AMAROS Era A Dutch Population-based Study in t
Ingrid G. M. Poodt (2017)
10.1111/ans.15173
Predicting non‐sentinel lymph node metastasis in Australian breast cancer patients: are the nomograms still useful in the post‐Z0011 era?
G. Tapia (2019)
10.1007/s10147-010-0106-1
Clinicopathological features and treatment strategy for triple-negative breast cancer
Y. Yamamoto (2010)
10.1056/NEJMra1001389
Triple-negative breast cancer.
W. Foulkes (2010)
10.1007/s10549-010-1135-1
The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer
Z. Gabos (2010)
10.5958/2394-6792.2015.00022.8
Estrogen, Progesterone and Human epidermal growth factor receptor -2 in malignant breast lesions: A 5 year study in a tertiary care hospital of Karnataka
Sujoy Kumar De (2015)
10.1007/978-3-319-15907-2_13
Staging and Workup of Invasive Breast Cancer
V. Sacchini (2015)
Leveraging the clinical microsystem to offset the limitations of breast cancer screening in the united states
Frida Velcani (2019)
10.1038/srep45411
Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study
Y. Gong (2017)
10.1016/j.clon.2016.04.003
Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs.
K. Han (2016)
10.1016/j.breast.2014.02.013
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.
S. Lakis (2014)
10.1016/j.yexcr.2017.12.032
CHD4‐mediated loss of E‐cadherin determines metastatic ability in triple‐negative breast cancer cells
Chi-Wen Luo (2018)
10.1038/modpathol.2011.160
Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes
S. Park (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar